EA201892082A1 - MOSTIC BICYCLIC INHIBITORS MENIN-MLL AND METHODS OF USE - Google Patents

MOSTIC BICYCLIC INHIBITORS MENIN-MLL AND METHODS OF USE

Info

Publication number
EA201892082A1
EA201892082A1 EA201892082A EA201892082A EA201892082A1 EA 201892082 A1 EA201892082 A1 EA 201892082A1 EA 201892082 A EA201892082 A EA 201892082A EA 201892082 A EA201892082 A EA 201892082A EA 201892082 A1 EA201892082 A1 EA 201892082A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
menin
mll
mostic
bicyclic inhibitors
Prior art date
Application number
EA201892082A
Other languages
Russian (ru)
Other versions
EA039109B1 (en
Inventor
Тао Ву
Ляньшэн Ли
И Ван
Пингда Рен
Иоланта Грембека
Томаш Сирпики
Шимон Клоссовски
Джонатан Поллок
Дмитрий Боркин
Original Assignee
Кура Онколоджи, Инк.
Зе Реджентс Оф Зе Юниверсити Oф Мичиган
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Кура Онколоджи, Инк., Зе Реджентс Оф Зе Юниверсити Oф Мичиган filed Critical Кура Онколоджи, Инк.
Priority claimed from PCT/US2017/022535 external-priority patent/WO2017161002A1/en
Publication of EA201892082A1 publication Critical patent/EA201892082A1/en
Publication of EA039109B1 publication Critical patent/EA039109B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Abstract

В настоящем изобретении предлагаются способы ингибирования взаимодействия менина с онкобелками MLL1, MLL2 и слитыми онкобелками MLL. Способы являются полезными для лечения лейкоза, рака с солидными опухолями, диабета и других заболеваний, зависимых от активности белков MLL1, MLL2, слитых белков MLL и/или менина. Также предлагаются композиции для применения в этих способах.The present invention provides methods for inhibiting the interaction of menin with MLL1, MLL2 oncoproteins and MLL oncoproteins fused. The methods are useful for the treatment of leukemia, cancer with solid tumors, diabetes and other diseases dependent on the activity of MLL1, MLL2 proteins, MLL and / or menin fused proteins. Compositions for use in these methods are also provided.

EA201892082A 2016-12-07 2017-03-15 Bridged bicyclic inhibitors of menin-mll interaction and methods of use EA039109B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662431387P 2016-12-07 2016-12-07
PCT/US2017/022535 WO2017161002A1 (en) 2016-03-16 2017-03-15 Bridged bicyclic inhibitors of menin-mll and methods of use

Publications (2)

Publication Number Publication Date
EA201892082A1 true EA201892082A1 (en) 2019-04-30
EA039109B1 EA039109B1 (en) 2021-12-06

Family

ID=66436977

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201892082A EA039109B1 (en) 2016-12-07 2017-03-15 Bridged bicyclic inhibitors of menin-mll interaction and methods of use

Country Status (1)

Country Link
EA (1) EA039109B1 (en)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2610655A1 (en) * 2005-06-03 2006-12-14 Abbott Laboratories Cyclobutyl amine derivatives
WO2008070303A2 (en) * 2006-10-19 2008-06-12 The University Of Chicago Therapeutics to inhibit mll-menin interaction for treating leukemia
JP2016512514A (en) * 2013-03-13 2016-04-28 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン Compositions containing thienopyrimidine and thienopyridine compounds and methods for their use
US9212180B2 (en) * 2013-06-12 2015-12-15 The Regents Of The University Of Michigan Menin-MLL inhibitors and methods of use thereof
CA2944669A1 (en) * 2014-04-04 2015-10-08 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
US20170119769A1 (en) * 2014-06-10 2017-05-04 The Trustees Of The University Of Pennsylvania Scaffolds for inhibitors of menin-mll interactions

Also Published As

Publication number Publication date
EA039109B1 (en) 2021-12-06

Similar Documents

Publication Publication Date Title
PH12018501955A1 (en) Bridged bicyclic inhibitors of menin-mll and methods of use
PH12018501952A1 (en) Substituted inhibitors of menin-mill and methods of use
EA201792583A1 (en) METHODS AND COMPOSITIONS FOR INHIBITING THE INTERACTION OF MENIN WITH MLL PROTEINS
EA202191852A1 (en) IRREVERSIBLE INHIBITORS OF THE MENIN-MLL INTERACTION
EA201791867A1 (en) BICYCLIC HETEROCYCLES AS FGFR4 INHIBITORS
EA201800444A1 (en) DERIVATIVES OF MAYTANZINOID, THEIR CONJUGATES AND METHODS OF USE
GEP20217326B (en) Constructs having a sirp-alpha domain or variant thereof
EA202090516A3 (en) BICYCLIC HETEROCYCLES AS FGFR INHIBITORS
EA201791706A1 (en) ICOS BINDING PROTEINS
MX2015011576A (en) Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof.
EA201991214A1 (en) ANTIBODIES AGAINST PD-1 AND THEIR COMPOSITION
CY1122243T1 (en) N-PYRIDINYLACETAMIDE DERIVATIVES AS WNT SIGNALING PATHWAY INHIBITORS
EA201690502A1 (en) SUBSTITUTED PYRIMIDINE INHIBITORS BMI-1
BR112017013568A2 (en) fused bicyclic compounds for treating diseases
EA201890158A1 (en) ANTIBODIES AGAINST NTB-A AND RELATED COMPOSITIONS AND METHODS
MX2019001471A (en) Anti-siglec-7 antibodies for the treatment of cancer.
EA202090204A1 (en) ANTI-CD137 ANTIBODIES
EA201892802A1 (en) Derivatives of adenosine for use in the treatment of cancer
MX2021014286A (en) Multispecific proteins.
EA201692100A1 (en) NEW ANTIBODIES AGAINST RNF43 AND METHODS OF THEIR APPLICATION
BR112019017403A2 (en) compositions and methods for the treatment of cancer
WO2018138032A3 (en) NKp46 BINDING AGENTS
CO2017010621A2 (en) Fused bicyclic compounds for the treatment of diseases
EA202091567A1 (en) CHIMERIC PROTEINS MIT
EA201591421A1 (en) DRUGS OF POLYPEPTIDE FACTOR IX